 phase I/II trial zidovudine interferon-alpha granulocyte-macrophage colony-stimulating factor treatment human immunodeficiency virus type infection patients human immunodeficiency virus type counts cells/l granulocyte-macrophage colony-stimulating factor GM-CSF combination zidovudine escalating doses daily subcutaneous interferon-alpha Mean neutropenia-inducing doses interferon-alpha IU/day groups mg Mean GM-CSF doses neutropenia microgram/kg/day groups mean minimum effective GM-CSF dose microgram/kg/day Serum antigen antigenemic patients Toxicities dose-dependent increase lymphokine-like side effects anorexia weight loss fatigue anemia toxicities combination significant low-dose GM-CSF zidovudine interferon-alpha therapy antiviral properties combination